FDA Approves Radioembolization Therapy for Unresectable Hepatocellular Carcinoma
The use of SIR-Spheres achieved a 98.5 percent overall response rate in the treatment of hepatocellular carcinoma in a recent prospective multicenter trial.
Interventional radiologists have a new modality for treating hepatocellular carcinoma (HCC) with the Food and Drug Administration (FDA) issuing an expanded approval for SIR-Spheres Y-90 resin microspheres in the management of unresectable HCC.
Previously approved for the treatment of metastatic colorectal cancer, the SIR-Spheres radioembolization therapy was recently evaluated for the treatment of HCC in the prospective multicenter DOORwaY90 study.
In a prospective multicenter study of SIR-Spheres, researchers found that the median duration of response for patients with hepatocellular carcinoma (HCC) exceeded 300 days. The FDA recently granted an expanded approval of SIR-Spheres for treating unresectable HCC. (Image courtesy of Sirtex Medical.)
Employing personalized dosimetry for the direct delivery of optimal radiation dosing to HCC tumors, researchers found that SIR-Spheres (Sirtex Medical) achieved a 98.5 percent overall response rate, and that the median duration of response exceeded 300 days.
“This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results. This will give multidisciplinary care teams the confidence to recommend SIR-Spheres for HCC treatment,” noted Armeen Mahvash, M.D., a professor in the Department of Interventional Radiology at the University of Texas MD Anderson Cancer Center in Houston, and a co-principal investigator of the DOORwaY90 study.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
